331 related articles for article (PubMed ID: 26297574)
1. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial.
Wilken R; Li CS; Sharon VR; Kim K; Patel FB; Patel F; Maverakis E
Trials; 2015 Aug; 16():374. PubMed ID: 26297574
[TBL] [Abstract][Full Text] [Related]
2. Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism.
Nguyen VT; Farman N; Maubec E; Nassar D; Desposito D; Waeckel L; Aractingi S; Jaisser F
J Invest Dermatol; 2016 Oct; 136(10):2080-2089. PubMed ID: 27262545
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of '0.05% Clobetasol + 2.5% zinc sulphate' cream vs. '0.05% Clobetasol alone' cream in the treatment of the chronic hand eczema: a double-blind study.
Faghihi G; Iraji F; Shahingohar A; Saidat A
J Eur Acad Dermatol Venereol; 2008 May; 22(5):531-6. PubMed ID: 18284511
[TBL] [Abstract][Full Text] [Related]
5. Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A 4-week, randomized, double-blind clinical trial.
Corrocher G; Di Lorenzo G; Mansueto P; Martinelli N; Esposito-Pellitteri M; Gelio S; Lombardo G; Pacor ML
Clin Ther; 2006 Sep; 28(9):1296-302. PubMed ID: 17062302
[TBL] [Abstract][Full Text] [Related]
6. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
Hudson CP; Kempers S; Menter A; Papp K; Smith S; Sofen H; Colón LE; Johnson LA; Gottschalk R
Cutis; 2011 Oct; 88(4):201-7. PubMed ID: 22106730
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial.
Lenane P; Macarthur C; Parkin PC; Krafchik B; DeGroot J; Khambalia A; Pope E
JAMA Dermatol; 2014 Jan; 150(1):47-50. PubMed ID: 24226568
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Koizumi N; Inatomi T; Shirakata Y; Ikezawa Z; Hashimoto K; Kinoshita S
Ophthalmology; 2009 Apr; 116(4):685-90. PubMed ID: 19243825
[TBL] [Abstract][Full Text] [Related]
9. Topical clobetasol in conjunction with topical tretinoin is effective in preventing scar formation after superficial partial-thickness burn ulcers of the skin: A retrospective study.
Taheri A; Moradi Tuchayi S; Alinia H; Orscheln CS; Mansoori P; Feldman SR
J Dermatolog Treat; 2015; 26(4):361-4. PubMed ID: 25424054
[TBL] [Abstract][Full Text] [Related]
10. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial.
Campisi G; Giandalia G; De Caro V; Di Liberto C; Aricò P; Giannola LI
Br J Dermatol; 2004 May; 150(5):984-90. PubMed ID: 15149513
[TBL] [Abstract][Full Text] [Related]
11. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
12. Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
Maubec E; Laouénan C; Deschamps L; Nguyen VT; Scheer-Senyarich I; Wackenheim-Jacobs AC; Steff M; Duhamel S; Tubiana S; Brahimi N; Leclerc-Mercier S; Crickx B; Perret C; Aractingi S; Escoubet B; Duval X; Arnaud P; Jaisser F; Mentré F; Farman N
J Invest Dermatol; 2015 Jul; 135(7):1781-1789. PubMed ID: 25668238
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial.
Sonthalia S; Singal A
Int J Dermatol; 2012 Nov; 51(11):1371-8. PubMed ID: 23067089
[TBL] [Abstract][Full Text] [Related]
14. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability.
Virgili A; Borghi A; Toni G; Minghetti S; Corazza M
Br J Dermatol; 2014 Aug; 171(2):388-96. PubMed ID: 24641522
[TBL] [Abstract][Full Text] [Related]
15. UV-A1 phototherapy vs clobetasol propionate, 0.05%, in the treatment of vulvar lichen sclerosus: a randomized clinical trial.
Terras S; Gambichler T; Moritz RK; Stücker M; Kreuter A
JAMA Dermatol; 2014 Jun; 150(6):621-7. PubMed ID: 24696010
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
[TBL] [Abstract][Full Text] [Related]
17. Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria: a randomized, double-blind, placebo-controlled trial.
Vena GA; Cassano N; D'Argento V; Milani M
Br J Dermatol; 2006 Feb; 154(2):353-6. PubMed ID: 16433809
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus.
Funaro D; Lovett A; Leroux N; Powell J
J Am Acad Dermatol; 2014 Jul; 71(1):84-91. PubMed ID: 24704090
[TBL] [Abstract][Full Text] [Related]
19. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
Uliasz A; Zeichner J; Soung J; Wong V; Lebwohl M
Cutis; 2008 Jun; 81(6):517-9. PubMed ID: 18666395
[TBL] [Abstract][Full Text] [Related]
20. The reservoir effect of topical steroids in vitiliginous skin: A cross-sectional study.
Singh SK; Nasir F
Indian J Dermatol Venereol Leprol; 2015; 81(4):370-5. PubMed ID: 26144851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
